- Home
- INCR vs ADAG Comparison
INCR vs ADAG Comparison
Compare INCR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ADAG
- Stock Information
- Founded
- INCR 1994
- ADAG 2011
- Country
- INCR Israel
- ADAG China
- Employees
- INCR N/A
- ADAG N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- ADAG Health Care
- Exchange
- INCR Nasdaq
- ADAG Nasdaq
- Market Cap
- INCR 76.7M
- ADAG 76.3M
- IPO Year
- INCR N/A
- ADAG 2021
- Fundamental
- Price
- INCR $1.58
- ADAG $2.06
- Analyst Decision
- INCR
- ADAG Strong Buy
- Analyst Count
- INCR 0
- ADAG 1
- Target Price
- INCR N/A
- ADAG $8.00
- AVG Volume (30 Days)
- INCR 8.6K
- ADAG 21.4K
- Earning Date
- INCR 05-01-2025
- ADAG 07-24-2025
- Dividend Yield
- INCR N/A
- ADAG N/A
- EPS Growth
- INCR N/A
- ADAG N/A
- EPS
- INCR N/A
- ADAG N/A
- Revenue
- INCR $65,575,323.00
- ADAG $103,204.00
- Revenue This Year
- INCR $69.54
- ADAG $6,488.89
- Revenue Next Year
- INCR $41.75
- ADAG $57.50
- P/E Ratio
- INCR N/A
- ADAG N/A
- Revenue Growth
- INCR N/A
- ADAG N/A
- 52 Week Low
- INCR $1.17
- ADAG $1.33
- 52 Week High
- INCR $3.28
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- INCR 55.03
- ADAG 57.43
- Support Level
- INCR $1.51
- ADAG $1.80
- Resistance Level
- INCR $1.59
- ADAG $2.02
- Average True Range (ATR)
- INCR 0.05
- ADAG 0.12
- MACD
- INCR -0.00
- ADAG 0.02
- Stochastic Oscillator
- INCR 55.63
- ADAG 67.31
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.